Correction: A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy (2020)
Attributed to:
Understanding and Ameliorating perturbed signalling and pathogenesis in FSHD
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41417-020-00251-y
PubMed Identifier: 33177625
Publication URI: http://europepmc.org/abstract/MED/33177625
Type: Journal Article/Review
Parent Publication: Cancer Gene Therapy
Issue: 5
ISSN: 0929-1903